Federal Register / Vol. 75, No. 169 / Wednesday, September 1, 2010 / Notices 53721 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substances, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than November 1, 2010. 

Dated: August 2, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–21776 Filed 8–31–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a), Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on May 27, 2010, 

Archimica, Inc., 2460 W. Bennett Street, 

Springfield, Missouri 65807–1229, made 

application by renewal to the Drug 

Enforcement Administration (DEA) to 

be registered as a bulk manufacturer of 

the basic classes of controlled 

substances listed in schedule II: 

Drug Schedule 

Lisdexamfetamine (1205) ............. II 

Methylphenidate (1724) ................ II 

Phenylacetone (8501) .................. II 

Methadone Intermediate (9254) ... II 

The company plans to manufacture 

the listed controlled substances in bulk 

for distribution to its customers. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substances, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than November 1, 2010. 

Dated: August 2, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–21775 Filed 8–31–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a) of Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on May 14, 2010, 

Chattem Chemicals Inc., 3801 St. Elmo 

Avenue, Building 18, Chattanooga, 

Tennessee 37409, made application by 

renewal to the Drug Enforcement 

Administration (DEA) as a bulk 

manufacturer of the basic classes of 

controlled substances listed in 

schedules I and II: 

Drug Schedule 

4–Methoxyamphetamine (7411) ... I 

Dihydromorphine (9145) ............... I 

Amphetamine (1100) .................... II 

Methamphetamine (1105) ............ II 

Lisdexamfetamine (1205) ............. II 

Methylphenidate (1724) ................ II 

Pentobarbital (2270) ..................... II 

Codeine (9050) ............................. II 

Dihydrocodeine (9120) ................. II 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................ II 

Hydrocodone (9193) ..................... II 

Meperidine (9230) ........................ II 

Methadone (9250) ........................ II 

Methadone intermediate (9254) ... II 

Morphine (9300) ........................... II 

Oripavine (9330) ........................... II 

Thebaine (9333) ........................... II 

Oxymorphone (9652) ................... II 

Noroxymorphone (9668) .............. II 

Alfentanil (9737) ........................... II 

Remifentanil (9739) ...................... II 

Sufentanil (9740) .......................... II 

Fentanyl (9801) ............................ II 

The company plans to manufacture 

the listed controlled substances in bulk 

for distribution to its customers. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substances, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than November 1, 2010. 

Dated: August 2, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–21773 Filed 8–31–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a) of Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on May 4, 2010, 

Cambrex Charles City, Inc., 1205 11th 

Street, Charles City, Iowa 50616, made 

application by renewal to the Drug 

Enforcement Administration (DEA) to 

be registered as a bulk manufacturer of 

the basic classes of controlled 

substances listed in schedule II: 

Drug Schedule 

Amphetamine (1100) .................... II 

Methamphetamine (1105) ............ II 

Lisdexamfetamine (1205) ............. II 

Methylphenidate (1724) ................ II 

Phenylacetone (8501) .................. II 

Codeine (9050) ............................. II 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................ II 

Dextropropoxyphene, bulk ........... II 

(non-dosage forms) (9273).

Morphine (9300) ........................... II 

Thebaine (9333) ........................... II 

Raw Opium (9600) ....................... II 

Opium extracts (9610) .................. II 

Opium, powdered (9639) ............. II 

Opium, granulated (9640) ............ II 

Poppy Straw (9650) ..................... II 

Oxymorphone (9652) ................... II 

Concentrate of Poppy Straw 

(9670).

II 

Sufentanil (9740) .......................... II 

Fentanyl (9801) ............................ II 

The company plans to manufacture 

the listed controlled substances in bulk 

for sale to its customers. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substances, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than November 1, 2010. 


hsrobinson on DSK69SOYB1PROD with NOTICES
53722 Federal Register / Vol. 75, No. 169 / Wednesday, September 1, 2010 / Notices 

Dated: August 2, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–21772 Filed 8–31–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a) of Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on May 14, 2010, 

Chattem Chemicals Inc., 3801 St. Elmo 

Avenue, Building 18, Chattanooga, 

Tennessee 37409, made application to 

the Drug Enforcement Administration 

(DEA) as a bulk manufacturer of the 

basic classes of controlled substances 

listed in schedule II: 

Drug Schedule 

Phenylacetone (8501) .................. II 

Raw Opium (9600) ....................... II 

Concentrate of Poppy Straw 

(9670).

II 

The company plans to manufacture 

the listed controlled substances in bulk 

for distribution to its customers. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substances, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL),8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than November 1, 2010. 

Dated: August 13, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–21744 Filed 8–31–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated March 16, 2010, and 

published in the Federal Register on 

March 24, 2010, (75 FR 14189), Rhodes 

Technologies, 498 Washington Street, 

Coventry, Rhode Island 02816, made 

application by renewal to the Drug 

Enforcement Administration (DEA) to 

be registered as a bulk manufacturer of 

the basic classes of controlled 

substances listed in schedules I and II: 

Drug Schedule 

Tetrahydrocannabinols (7370) ..... I 

Methylphenidate (1724) ................ II 

Codeine (9050) ............................. II 

Dihydrocodeine (9120) ................. II 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................ II 

Hydrocodone (9193) ..................... II 

Oripavine (9330) ........................... II 

Thebaine (9333) ........................... II 

Oxymorphone (9652) ................... II 

Noroxymorphone (9668) .............. II 

Fentanyl (9801) ............................ II 

The company plans to manufacture 

the listed controlled substances in bulk 

for conversion and sale to dosage form 

manufacturers. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Rhodes Technologies to manufacture 

the listed basic classes of controlled 

substances is consistent with the public 

interest at this time. DEA has 

investigated Rhodes Technologies to 

ensure that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823(a), 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: August 2, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–21782 Filed 8–31–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated March 16, 2010, and 

published in the Federal Register on 

March 24, 2010, (75 FR 14189), 

Archimica, Inc., 2460 W. Bennett Street, 

Springfield, Missouri 65807–1229, made 

application by letter to the Drug 

Enforcement Administration (DEA) to 

be registered as a bulk manufacturer of 

Amphetamine (1100), a basic class of 

controlled substance listed in schedule 

II. 

The company plans to acquire the 

listed controlled substance in bulk from 

a domestic source in order to 

manufacture other controlled substances 

in bulk for distribution to its customers. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Archimica, Inc., to manufacture the 

listed basic class of controlled substance 

is consistent with the public interest at 

this time. DEA has investigated 

Archimica, Inc., to ensure that the 

company’s registration is consistent 

with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823(a), 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic class of controlled substance 

listed. 

Dated: August 13, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–21780 Filed 8–31–10; 8:45 am] 

BILLING CODE 4410–09–P 

NATIONAL SCIENCE FOUNDATION 

Proposal Review; Notice of Meetings 

In accordance with the Federal 

Advisory Committee Act (Pub. L. 92– 

463, as amended), the National Science 

Foundation (NSF) announces its intent 

to hold proposal review meetings 

throughout the year. The purpose of 

these meetings is to provide advice and 

recommendations concerning proposals 

submitted to the NSF for financial 

support. The agenda for each of these 

meetings is to review and evaluate 

proposals as part of the selection 

process for awards. The review and 

evaluation may also include assessment 

of the progress of awarded proposals. 

The majority of these meetings will take 

place at NSF, 4201 Wilson Blvd., 

Arlington, Virginia 22230. 

These meetings will be closed to the 

public. The proposals being reviewed 

include information of a proprietary or 

confidential nature, including technical 

information; financial data, such as 


hsrobinson on DSK69SOYB1PROD with NOTICES